The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

Viking Therapeutics (VKTX) shares crashed nearly 29% in todays trade after the companys much-anticipated weight-loss pill ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

Viking Therapeutics (VKTX) stock plunges and short sellers betting against the company gain $521M amid the selloff. Read more here.

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Viking Therapeutics, with a price target of $71.00. The company’s shares closed last Friday at $40.03. Take ...

In the second quarter, attributable net income increased by 45 percent to 1.5 billion yuan from 1.067 billion yuan in the ...

Viking Therapeutics Inc (NASDAQ: VKTX) reported new clinical data for its oral obesity drug – sending shares sharply lower as ...

Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off ...

In a report released today, Jay Olson from Oppenheimer reiterated a Buy rating on Viking Therapeutics, with a price target of $100.00. The company’s shares opened today at $40.97. Take advantage of ...

Viking Therapeutics said Tuesday its experimental weight-loss pill helped patients lose 12.2% of their body weight in a ...